Media Monitors Obtains Technology Patent: related news

Media Monitors Obtains Technology Patent

White Plains, NY - Jul 10, 2008 - The U.S. Patent and Trademark Office has issued patent #US 7,386,047 B2 for Media Monitors' method for determining likelihood of matches between source data and reference data, which was filed Aug. 19, 2003. This patent covers the data gathering and research firm's fingerprinting technology. In this process, retrieved audio samples are analyzed by the patented algorithm that enables Media Monitors to accurately identify additional occurrences. This unique technology helps Media Monitors process millions of pieces of data and deliver an accurate picture of what was aired on radio, TV and cable TV.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Applied Nanoscience Receives Additional Patent Coverage on Core Technology Platform

CARLSBAD, CA -- (MARKET WIRE) -- 07/23/08 -- Applied Nanoscience Inc. (ANI) (APNN), a nanotechnology-based filtration development company, today announced that it has been issued a patent in New Zealand for its core technology platform encompassing "Filtering Devices Incorporating Nanoparticles." The patent covers three main methods of associating nanoparticles with filter media: (1) having pellets of nanoparticles located adjacent to the filter media; (2) coating the filter media with a powder of nanoparticles; and, (3) impregnating the nanoparticles into the filter media.

Alnylam Loses Challenge In Europe On Key Patent Covering Gene-Silencing Technology

July 14, 2008 (FinancialWire) Shares of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell after the company said that it lost a challenge in Europe on a key patent which covered certain areas of its gene-silencing technology. Alnylam said claims on the "Glover" patent were overturned by the Opposition Division of the European Patent Office. The patent is licensed from Cancer Research Technology Ltd. and Alnylam said it plans to appeal the decision. Alnylam said that the decision does not alter the position of the company's intellectual property for developing and commercializing RNAi therapeutics, nor does it impact any ongoing business development discussions. The patent is one of 11 held by Alnylam. The goal of gene-silencing, or RNA-based, treatments is to turn off, or silence- the gene at the root of a medical condition, treating the a

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Patent Granted in Mexico for Breakthrough CodecSys Video Compression Technology from Broadcast International

today announced that a patent for its breakthrough multi-codec video compression technology, CodecSys, has been granted by the Mexico patent office. The technology slashes bandwidth requirements for video transmitted over satellite, cable, IP, and wireless media. CodecSys allows, for example, up to twelve HDTV channels to be broadcast over the same media which currently support only two.

Oberon Media Unveils Revolutionary, Patent-pending Technology to Bring One-to-one Marketing to Downloadable Games

SEATTLE, BUSINESS WIRE -- Casual Connect - Oberon Media, the world's leading multi-platform casual-games company, today unveiled its new, patent-pending marketing tool, SweetSpot Technology(TM). SweetSpot Technology combines a state-of-the-art personalization engine with advanced heuristics and an adaptive UI framework to bring one-to-one marketing to downloadable casual games.

Oberon Media Unveils Revolutionary, Patent-pending Technology to Bring One-to-one Marketing to Downloadable Games

SEATTLE--(BUSINESS WIRE)--July 23, 2008--Casual Connect - Oberon Media, the world’s leading multi-platform casual-games company, today unveiled its new, patent-pending marketing tool, SweetSpot Technology(tm). SweetSpot Technology combines a state-of-the-art personalization engine with advanced heuristics and an adaptive UI framework to bring one-to-one marketing to downloadable casual games.

The Evolution of Online Media Search Gives Birth to Dizzler; A Free Interactive, Playable Media Search Engine and Aggregator of Multi-Media Content

SCOTTSDALE, Ariz., July 16 /PRNewswire/ -- (ZealousPR) -- Free music and multi-media mega-search engine and media player giant, Dizzler, announces official website launch and established presence in the playable media search technology arena today at http://www.Dizzler.com.

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling...

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill) CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware.

Rim Semiconductor Files Patent Application

July 10, 2008 (FinancialWire) Rim Semiconductor Co. (OTCBB: RSMI) (Current Market Cap. US$356,698.00) filed a non-provisional patent application on its RQAM technology. Rim Semi s Cupria transport processor is based on this RQAM technology, and is able to drive data traffic at more than 40 megabits per second. Existing technologies are able to drive data 15 mbps at this distance on this wire type. The patent, titled Amplitude Modulation Decoder, was filed as a non-provisional patent with the United States Patent and Trademark Office. It was also filed under the Patent Cooperation Treaty. This protects Rim Semi s intellectual property rights across a wide geography. Other companies trading in Rim Semi s industry include ABB Ltd. (NYSE: ABB), Eaton Corp.

MSM Noticing That Patent Gridlock Stunts Innovation

trichard tips a column on the editorial page at that most traditional of mainstream media, the Wall Street Journal, arguing the point (obvious to this community for a decade) that the US patent system costs more than the value it delivers. The columnist is L. Gordon Crovitz and here is an excerpt: "New drugs require great specificity to earn a patent, whereas patents are often granted to broad, thus vague, innovations in software, communications, and other technologies. Ironically, the aggregate value of these technology patents is then wiped out through litigation costs. Our patent system [is] a disincentive at a time when we expect software and other technology companies to be the growth engine of the economy. Imagine how much more productive our information-driven economy would be if the patent system lived up to the intention of the F

MIT sues Affymetrix for patent infringement

Affymetrix, the Santa Clara maker of tools used to study DNA and diagnose diseases, was sued for patent infringement by the Massachusetts Institute of Technology over the company's GeneChip system used to analyze genes. Affymetrix has knowingly infringed the patent, MIT and a company started by an MIT professor said in a federal court complaint filed Tuesday in Boston. Affymetrix filed an application with the U.S. Patent and Trademark Office in September 2004, six months after a similar patent was approved for MIT, the university said in its complaint. The patent regulators ruled in May 2007 that the MIT group was the first inventor, according to the complaint. The GeneChip technology is used to develop new therapeutic drugs and to investigate the cause of cancer, AIDS and other diseases, Affymetrix has said.

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill)

CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware. "The mathematics and science behind Engagement Milling are revolutionary, and we have incorporated that technology into our SURFCAM product line as TrueMill(R).

Mexens Technology (Navizon) receives patent for GPS/Wireless positioning

Mexens Technology, the maker of the Navizon software, yesterday announced that it has received a patent from the US Patent and Trademark Office for its "System and Method for Enabling Continuous Geographic Location Estimation for Wireless Computing Devices" (US Patent No. 7397424). The patent consists of a system combining GPS and Wireless signals (Wi-Fi and/or cellular) to determine a position. When GPS signal is not available then the system uses Wi-Fi or cellular triangulation.

OriginOil Files International Patent for Quantum Fracturing Technology

LOS ANGELES--(BUSINESS WIRE)--OriginOil, Inc. (OTCBB:OOIL), the developer of a breakthrough technology to transform algae, the most promising source of renewable oil, into a true competitor to petroleum, has recently deposited an international PCT patent application pursuant to last year's filing of United States patent application 11/829,883 with the United States Patent Office. The international application is related to OriginOil's first patent application to optimize the growth and harvesting of algae cells.

Cosmo Pharmaceuticals awarded US patent for use of its MMX technology

Lainate, Italy – August 4, 2008 – Cosmo Pharmaceuticals, (SWX:COPN) a specialty pharma company that aims to become a global leader in optimised therapies for certain Gastrointestinal (GI) diseases, announced today that the US Trademark and Patent Office has issued a “notice of allowance� for its “controlled release and taste masking oral pharmaceutical compositions� better known as the MMX™ technology patent. This patent will expire in 2020, not considering possible SPCs. The patent was previously granted in Europe in 2003 and in other countries outside the US.

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

Health Discovery Corporation (HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

Collegium Pharmaceutical Inc. Announces U.S. Patent Issued Covering its DETERx(TM) Abuse Deterrent Sustained Release Technology

CUMBERLAND, R.I.--(BUSINESS WIRE)--July 16, 2008 - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that a new patent has been issued by the U.S. Patent and Trademark Office (USPTO) relating to its tamper resistant, abuse-deterrent formulation platform. US Patent Number 7,399,488 contains claims that cover orally administrable compositions comprising Collegium's proprietary micro-particle formulations. The formulations are designed to be more resistant to physical methods of tampering than currently available sustained release dosage forms. US Patent No. 7,399,488 will provide protection for DETERx(TM) and products incorporating the DETERx(TM) technology into the year 2025.

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

Health Discovery Corporation (OTCBB:HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

Search took 0.46 seconds.